CRS members receive a free online subscription
Drug Delivery and Translational Research is a journal published by CRS, providing a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. The journal is published 6 times a year and will be available online to CRS members as part of their annual dues.
We welcome research focused on the following areas of translational drug delivery research:
- Designing and developing novel drug delivery systems, with a focus on their application to disease conditions
- Preclinical and clinical data related to drug delivery systems
- Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes
- Short-term and long-term biocompatibility of drug delivery systems, host response
- Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering
- Image-guided drug therapy
- Devices for drug delivery and drug/device combination products
In addition to original full-length papers, communications, and reviews, the journal will also include editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of CRS.
"In this 'Inspirational Note' you will be inspired by the way industry sees advances in drug delivery and Nanomedicine. Dr. Marianne Ashford talks about the 'increasing momentum'. You should not miss this note if you are interested in translational research." -Prof. Maria José Alonso, Editor-in-Chief of the Drug Delivery and Translational Research (DDTR) Journal, Past President of the Controlled Release Society
Latest Issue of DDTR: 22nd International Symposium on Microencapsulation Special Issue
December 2020: Emerging Trends in Nano- and Microencapsulation Science
Best Paper of the December 2020 Issue of DDTR: Convection-enhanced delivery of liposomal drugs for effective treatment of glioblastoma multiforme
Summary: Convection-enhanced delivery (CED) is developed to infuse drugs directly into the brain using a catheter with a continuous positive pressure, thus overcoming the limitations of intravascular delivery such as blood-brain barrier. However, tissue distribution and retention of the infused drugs in the brain are significantly hindered by microenvironmental factors of the brain such as the extracellular matrix and lymphatic drainage system. In this work, we precisely engineered liposomal formulations to improve the therapeutic efficacy of CED for the treatment of glioblastoma. We found that PEGylated liposomal formulations incorporated with cationic lipids at the proper molar ratio exhibited specific cellular uptake in the glioblastoma cells in vitro, and efficient tissue distribution and retention in the brain tumor after CED. We believe that liposomal drugs engineered based on the biophysical properties of disease microenvironments will be widely used to improve the therapeutic efficacy of CED for the treatment of brain diseases.
2019 DDTR Best Paper of the Year: Depletion of collagen by losartan to improve tumor accumulation and therapeutic efficacy of photodynamic nanoplatforms
2019 CRS Nanomedicine and Nanoscale Delivery (NND) Best Paper of the Year: Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses
2019 DDTR CRS Oral Drug Delivery Focus Group Paper of the Year Award: Loratadine self-microemulsifying drug delivery systems (SMEDDS) in combination with sulforaphane for the synergistic chemoprevention of pancreatic cancer
Read DDTR's First Inspirational Note: Contraceptive technologies for global health: ethically getting to safe, effective and acceptable options for women and men
Maria José Alonso, PhD - University of Santiago de Complotela, Spain